Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEFT-PANC: Neoadjuvant vs Upfront Surgery in Left Pancreatic Cancer
NCT07155629Phase 3Not yet recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, irinotecan, fluorouracil, gemcitabine, paclitaxel in pancreatic cancer (PC), sponsored by Helsinki University Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
oxaliplatinirinotecanfluorouracilgemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07155629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155629.